Bedrijfsoverzicht
Indaptus Therapeutics, Inc. is a clinical biotechnology firm dedicated to the development of immunotherapy products designed to target both anti-cancer and anti-viral conditions, with its lead clinical candidate, Decoy20, engineered for single agent or combination therapy-based durable responses. The company operates within the healthcare sector and specifically within the biotechnology industry, a field characterized by high research and development expenditures and significant regulatory hurdles before products reach the market. As of the latest available data, the company maintains a market capitalization of $4.73M and employs a staff of 5 individuals, reflecting a highly lean operational structure typical of early-stage biotech entities. These financial metrics indicate that Indaptus is a micro-cap company with minimal revenue generation relative to its cash reserves, suggesting it is still in a capital-intensive development phase where the primary asset value lies in its intellectual property pipeline rather than current commercial sales.
Financiële gezondheid
The company reports no revenue for the trailing twelve months, resulting in a net income loss of $-20,848,916 and an EBITDA of $-19,832,778, figures that highlight a cost structure dominated by research and development expenses rather than operating overhead. The free cash flow stands at $-8,159,969, indicating that the company is burning through its cash reserves to fund its clinical programs and operational activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is consistent with a biotechnology company that has not yet achieved commercial product sales to generate revenue streams. Despite the negative earnings, the company holds $8.51M in cash and carries $0 in debt, creating a balance sheet that is technically conservative regarding leverage but precarious regarding long-term solvency without external financing. The current ratio of 1.51 suggests that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for immediate operational needs. However, the return on equity of -587.6% and the return on assets of -148.9% reveal that management is currently unable to generate positive returns on shareholder capital or the total asset base due to the absence of profitability.
Waarderingsbeoordeling
The company does not have a trailing P/E ratio as earnings are negative, while the forward P/E is listed as -1.52, a metric that implies expectations of continued losses or a lack of traditional earnings-based valuation in the near term. The price-to-book ratio is 1.46, indicating that the market values the company's equity at a premium of 46% over its book value, likely driven by the intangible value of its clinical pipeline. Since revenue is zero, the price-to-sales ratio is N/A, and the EV/EBITDA stands at 0.19, suggesting that traditional valuation multiples are not applicable or are severely distorted by the lack of profitability and sales. The stock has traded between a 52-week low of $1.51 and a 52-week high of $19.91, meaning the current price sits significantly below the yearly peak and reflects high volatility typical of speculative biotech stocks. With a beta of 0.99, the stock exhibits price volatility that closely mirrors the broader market, indicating that its movements are not driven by unique idiosyncratic factors but rather by general market sentiment and sector-wide trends.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not generated sufficient revenue to calculate a growth rate, which implies that any future earnings expansion will depend entirely on the successful commercialization of its drug candidates. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically available for reinvestment but currently absorbed by operational losses. Consequently, Indaptus reinvests its limited resources into R&D and clinical trials rather than distributing cash to shareholders, a strategy necessary for survival in the biotechnology sector but one that offers no immediate income to investors. The overall growth and income profile is defined by high risk and zero current yield, relying entirely on the potential future success of the Decoy20 candidate to transition the company from a cash-burning entity to a profitable one.